不可吸收鼻腔填塞预防性使用抗生素的成本效果分析
本研究采用马尔可夫模型进行临床决策分析,评估不可吸收鼻腔填塞时预防性使用抗生素是否具有成本效果。结果显示抗生素使用的增量成本效果比为334,493美元/QALY,在50,000美元/QALY的支付意愿下,不处方抗生素在98.0%的迭代中具有成本效果。结论认为常规抗生素预防不可吸收鼻腔填塞不具成本效果,应重新考虑。
要点
- 不可吸收鼻腔填塞常规预防性使用抗生素不具成本效果。
- 当抗生素所致艰难梭菌结肠炎风险>910/100,000时,不处方抗生素具成本效果。
- 当鼻腔填塞后TSS发生率<49/100,000时,不处方抗生素具成本效果。
核心结论
- 常规抗生素预防在鼻腔填塞情况下不具成本效果,应重新考虑。
- 即使假设抗生素可预防TSS,抗生素使用的并发症风险后果更大。
研究设计与样本
- 临床决策分析,使用马尔可夫模型评估是否应给予抗生素。
- 研究对象为接受不可吸收鼻腔填塞的患者。
- 效用评分、概率和成本来自文献。
- 对模型假设进行了敏感性分析。
- 证据等级为3a。
主要发现
- 抗生素使用的增量成本效果比为334,493美元/QALY。
- 概率敏感性分析显示,在50,000美元/QALY支付意愿下,不处方抗生素在98.0%的迭代中具有成本效果。
- 敏感性分析显示,当抗生素所致CDC风险大于910/100,000时,不处方抗生素具成本效果。
- 敏感性分析显示,当鼻腔填塞后TSS发生率小于49/100,000例时,不处方抗生素具成本效果。
关键数值与推荐
- 在50,000美元/QALY支付意愿下,不处方抗生素在98.0%的迭代中具有成本效果。
- 抗生素所致CDC风险阈值:大于910/100,000时不处方抗生素具成本效果。
- 鼻腔填塞后TSS发生率阈值:小于49/100,000例时不处方抗生素具成本效果。
临床怎么用
- 对于不可吸收鼻腔填塞患者,应重新考虑常规预防性使用抗生素的做法。
- 临床决策需权衡TSS预防与抗生素相关并发症(如艰难梭菌结肠炎)的风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Nonabsorbable nasal packing is often placed for the treatment of epistaxis or after sinonasal or skull base surgery. Antibiotics are often prescribed to prevent toxic shock syndrome (TSS), a rare, potentially fatal occurrence. However, the risk of TSS must be balanced against the major risk of antibiotic use, specifically Clostridium difficile colitis (CDC). The purpose of this study is to evaluate in terms of cost-effectiveness whether antibiotics should be prescribed when nasal packing is placed. STUDY DESIGN: A clinical decision analysis was performed using a Markov model to evaluate whether antibiotics should be given. SETTING: Patients with nonabsorbable nasal packing placed. METHODS: Utility scores, probabilities, and costs were obtained from the literature. We assess the cost-effectiveness of antibiotic use when the risk of community-acquired CDC is balanced against the risk of TSS from nasal packing. Sensitivity analysis was performed for assumptions used in the model. RESULTS: The incremental cost-effectiveness ratio for antibiotic use was 334,493 US dollars (USD)/quality-adjusted life year (QALY). Probabilistic sensitivity analysis showed that not prescribing antibiotics was cost-effective in 98.0% of iterations at a willingness to pay of 50,000 USD/QALY. Sensitivity analysis showed that when the risk of CDC from antibiotics was greater than 910/100,000 or when the incidence of TSS after nasal packing was less than 49/100,000 cases, the decision to withhold antibiotics was cost-effective. CONCLUSIONS: Routine antibiotic prophylaxis in the setting of nasal packing is not cost-effective and should be reconsidered. Even if antibiotics are assumed to prevent TSS, the risk of complications from antibiotic use is of greater consequence. LEVEL OF EVIDENCE: 3a.
引用
- Maul X, Dincer BC, Wu AW, et al. A Clinical Decision Analysis for Use of Antibiotic Prophylaxis for Nonabsorbable Nasal Packing. Otolaryngol Head Neck Surg. 2021. PMID: 33588621. doi:10.1177/0194599820988740
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。